Skip to content
value.today

Soleno Therapeutics, Inc.

SLNOUnlisted company
$2.0 Blast known market cap, Mar 2026 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
annual
value.today research
Net income
$-25 M
value.today research
Employees
—

Soleno Therapeutics, Inc. in brief

Soleno Therapeutics, Inc. is an unlisted company in the Biotechnology industry, based in California, USA. It was founded in 1999. In its latest reported year it had sales of $0 M and a net loss of $25 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Soleno Therapeutics, Inc. timeline

2 events, 1999–2014
  1. 1999
  2. 🏁
    · approximate
    Founded
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of Soleno Therapeutics, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Soleno Therapeutics, Inc.

Acquisitions and changes
No longer listed: ticker SLNO is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$553 M$1.1 B$1.7 B$2.2 B2020202120222023202420252026

World rank over time

▲ up 15,280 places since 2020
2020-01-01: #18004#18,00420202021-01-01: #16501#16,50120212022-01-07: #27428#27,42820222022-12-25: #31050#31,05020222023-07-30: #24770#24,77020232024-01-05: #8023#8,02320242026-03-08: #2724#2,7242026

Rank in USA: #3,590 (Jan 2020) · #3,419 (Jan 2021) · #5,095 (Jan 2022) · #5,509 (Dec 2022) · #4,673 (Jul 2023) · #1,951 (Jan 2024) · #480 (Mar 2026)

Annual results

Revenue
$0 M
Operating income
—
Net income
$-25 M

Mutual funds holding Soleno Therapeutics, Inc.#

1 funds hold shares worth $1 M. Since their previous reports 0 added shares and 167 sold, selling $571 M net.
Mutual funds holding Soleno Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC26,523$1 M—0.77%—Apr 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Markets and events: Soleno Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-05-15
4.4 M
2.31 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-05-15 23:50 UTC, code D, resumed 04:00 UTC
  • 2026-04-06 10:55 UTC, code T3, resumed 11:30 UTC
  • 2025-03-26 20:03 UTC, code T3, resumed 22:45 UTC

Fails to deliver

  • : 201 shares at $53.01
  • : 64,409 shares at $53.01
  • : 64,482 shares at $53.01
  • : 194,854 shares at $52.99
  • : 34,067 shares at $52.95

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Where Soleno Therapeutics, Inc. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Soleno Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Soleno Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Lobbying by Soleno Therapeutics, Inc.#

$200 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$200 K
#1,003 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$220 K
  • Health Issues4 reports

Lobbying firms hired in 2025

THE KPM GROUP DC LLC $200 K

Soleno Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$220 K$220 K6
2025$200 K—4
2024$210 K—4
2023$140 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Soleno Therapeutics, Inc.” and “SOLENO THERAPEUTICS, INC.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Soleno Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $150 K a year.

Certified, FY2026
1
#1,897 among companies on value.today
Worker positions
1
Median wage offered
$150 K
a year, full-time
Applications filed
1
Soleno Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Business Systems ManagerInformation Technology Project Managers1$150 K

Where: Redwood City, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Soleno Therapeutics, Inc.

FDA drug approvals: Soleno Therapeutics, Inc.#

1 approved applications held; 1 approvals and 0 new uses in 2025.

Approvals held
1
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
Soleno Therapeutics, Inc.: latest FDA approvals
ApprovedDrugKind
2025-03-26Vykat XrDiazoxide Choline · NDA216665New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (SOLENO), so they follow acquisitions

How Soleno Therapeutics, Inc. compares in Biotechnology

  • Revenue$0 M · higher than 0% of 647

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Soleno Therapeutics, Inc.🇺🇸$2.0 B———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Mar 8, 2026 (last known)
Profile updated:
Nov 14, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Soleno Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Soleno Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Soleno Therapeutics, Inc.? Suggest a correction